Last reviewed · How we verify
Bipolar disorder in remission
Approved treatments
- Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Lithium Citrate · Hikma
Lithium Citrate works by inhibiting glycogen synthase kinase-3, a key enzyme involved in the regulation of various cellular processes. - Seroquel · AstraZeneca
- Phenytoin Sodium · Viatris
Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation. - Tegretol · Novartis AG (originally Geigy)
Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain. - Lamictal · GSK
- Zyprexa · Eli Lilly
- Risperdal · Johnson & Johnson (Janssen)
Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors for schizophrenia and bipolar disorder. - Geodon · Pfizer Inc.
Atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors with the least metabolic side effects in its class. - Abilify · Generic (originally Otsuka/BMS)
Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it. - Carbamazepin · Enanta Pharmaceuticals, Inc
- Lithobid · Generic (multiple manufacturers)
- phenobarbitone · Institute of Child Health
- Lithium Carbonate
- Mysoline · Bausch Health
- Dilantin · Pfizer
Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels. - Seroquel · University of Pittsburgh
- Quetiapin · Sykehuset Innlandet HF
- Risperdal · Ohio State University
- Zyprexa · Washington University School of Medicine
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Bipolar disorder in remission patent landscape — cliff calendar, originator estates, attackable patents
- Bipolar disorder in remission treatment landscape brief
- Bipolar disorder in remission treatment updates RSS
Frequently asked questions about Bipolar disorder in remission
What drugs treat Bipolar disorder in remission?
Tracked treatments include Abilify, Lithium Citrate, Seroquel, Phenytoin Sodium, Tegretol, Lamictal, Zyprexa, Risperdal.
What is the treatment for Bipolar disorder in remission?
Standard treatment for Bipolar disorder in remission includes Abilify, Lithium Citrate, Seroquel, Phenytoin Sodium, Tegretol. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Bipolar disorder in remission patent cliff · Bipolar disorder in remission CI report
- Treatment: Abilify · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Treatment: Lithium Citrate · Hikma
- Treatment: Seroquel · AstraZeneca
- Treatment: Phenytoin Sodium · Viatris
- Treatment: Tegretol · Novartis AG (originally Geigy)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing